Historical Valuation
Lexicon Pharmaceuticals Inc (LXRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.42 is considered Undervalued compared with the five-year average of -4.61. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 1.17 to 1.70 according to relative valuation methord. Compared to the current price of 1.17 USD , Lexicon Pharmaceuticals Inc is Undervalued By 0.01%.
Relative Value
Fair Zone
1.17-1.70
Current Price：1.17
0.01%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lexicon Pharmaceuticals Inc (LXRX) has a current Price-to-Book (P/B) ratio of 3.45. Compared to its 3-year average P/B ratio of 3.03 , the current P/B ratio is approximately 13.75% higher. Relative to its 5-year average P/B ratio of 3.62, the current P/B ratio is about -4.69% higher. Lexicon Pharmaceuticals Inc (LXRX) has a Forward Free Cash Flow (FCF) yield of approximately -17.52%. Compared to its 3-year average FCF yield of -39.47%, the current FCF yield is approximately -55.61% lower. Relative to its 5-year average FCF yield of -31.84% , the current FCF yield is about -44.97% lower.
P/B
Median3y
3.03
Median5y
3.62
FCF Yield
Median3y
-39.47
Median5y
-31.84
Competitors Valuation Multiple
AI Analysis for LXRX
The average P/S ratio for LXRX competitors is 33.57, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX.O) exhibits a P/S ratio of 20.42, which is -39.18% above the industry average. Given its robust revenue growth of 710.40%, this premium appears sustainable.
Performance Decomposition
AI Analysis for LXRX
1Y
3Y
5Y
Market capitalization of LXRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LXRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LXRX currently overvalued or undervalued?
Lexicon Pharmaceuticals Inc (LXRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 20.42 is considered Undervalued compared with the five-year average of -4.61. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 1.17 to 1.70 according to relative valuation methord. Compared to the current price of 1.17 USD , Lexicon Pharmaceuticals Inc is Undervalued By 0.01% .
What is Lexicon Pharmaceuticals Inc (LXRX) fair value?
LXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between 1.17 to 1.70 according to relative valuation methord.
How does LXRX's valuation metrics compare to the industry average?
The average P/S ratio for LXRX's competitors is 33.57, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX) exhibits a P/S ratio of 20.42, which is -39.18% above the industry average. Given its robust revenue growth of 710.40%, this premium appears sustainable.
What is the current P/B ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Jan 10 2026?
As of Jan 10 2026, Lexicon Pharmaceuticals Inc (LXRX) has a P/B ratio of 3.45. This indicates that the market values LXRX at 3.45 times its book value.
What is the current FCF Yield for Lexicon Pharmaceuticals Inc (LXRX) as of Jan 10 2026?
As of Jan 10 2026, Lexicon Pharmaceuticals Inc (LXRX) has a FCF Yield of -17.52%. This means that for every dollar of Lexicon Pharmaceuticals Inc’s market capitalization, the company generates -17.52 cents in free cash flow.
What is the current Forward P/E ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Jan 10 2026?
As of Jan 10 2026, Lexicon Pharmaceuticals Inc (LXRX) has a Forward P/E ratio of -4.15. This means the market is willing to pay $-4.15 for every dollar of Lexicon Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Jan 10 2026?
As of Jan 10 2026, Lexicon Pharmaceuticals Inc (LXRX) has a Forward P/S ratio of 20.42. This means the market is valuing LXRX at $20.42 for every dollar of expected revenue over the next 12 months.